Renovascular hypertension

M Kanitkar1

  • 1Pediatric Nephrology Unit, Department of Pediatrics, Command Hospital, Pune 411 040, India. madhurikanitkar@rediffmail.com

Indian Pediatrics
|February 8, 2005
PubMed

Insights

Renovascular hypertension, caused by kidney blood flow blockages, affects 3-10% of children with severe hypertension. Early diagnosis and treatment of renovascular lesions are crucial for managing this correctable condition.

Area of Science:

  • Pediatric Nephrology
  • Cardiovascular Medicine
  • Diagnostic Imaging

Background:

  • Renovascular hypertension stems from lesions impairing renal blood flow, affecting 3-10% of pediatric hypertension cases.
  • It is the second leading cause of correctable hypertension in children, after coarctation of the aorta.

Purpose of the Study:

  • To highlight the importance of systematic evaluation for identifying children with renovascular hypertension.
  • To discuss diagnostic investigations and therapeutic options for renovascular hypertension in children.

Main Methods:

  • Review of diagnostic modalities for renovascular hypertension, including invasive (renal arteriography) and non-invasive techniques (Doppler ultrasonography, CT/MR angiography).
  • Discussion of therapeutic interventions such as angioplasty, stenting, and surgical revascularization.

Main Results:

  • Renovascular lesions are found in a significant percentage of children evaluated for severe hypertension.
  • Non-invasive imaging techniques offer alternatives to invasive procedures like renal arteriography.

Conclusions:

  • Systematic evaluation aids pediatricians in selecting children likely to have renovascular hypertension, minimizing exposure to invasive diagnostics.
  • Available therapeutic options justify the diagnostic workup for renovascular hypertension, with interventions including angioplasty, stenting, and surgery.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...